BioPharma Dive reports that Seawolf, a developer of DNA therapeutics, has raised $100 million from investors including Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm. The company also disclosed a partnership with Sanofi that could reach $1.2 billion.
This funding and deal activity signals strong interest from major pharmaceutical companies in DNA-based therapies. For senior executives in pharma and biotech, these moves may indicate a shift in investment priorities and the potential for new collaborations or competitive pressures in the genetic medicines field.